HK1067492A1 - Method of making a homogenous doxorubicin-transferrin conjugate - Google Patents

Method of making a homogenous doxorubicin-transferrin conjugate

Info

Publication number
HK1067492A1
HK1067492A1 HK04108682.2A HK04108682A HK1067492A1 HK 1067492 A1 HK1067492 A1 HK 1067492A1 HK 04108682 A HK04108682 A HK 04108682A HK 1067492 A1 HK1067492 A1 HK 1067492A1
Authority
HK
Hong Kong
Prior art keywords
molecules
making
conjugate
drug
doxorubicin
Prior art date
Application number
HK04108682.2A
Other languages
English (en)
Inventor
Ward Page Faulk
Original Assignee
Faulk Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faulk Pharmaceuticals Inc filed Critical Faulk Pharmaceuticals Inc
Publication of HK1067492A1 publication Critical patent/HK1067492A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK04108682.2A 2001-05-15 2004-11-04 Method of making a homogenous doxorubicin-transferrin conjugate HK1067492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29068401P 2001-05-15 2001-05-15
US32953501P 2001-10-17 2001-10-17
PCT/US2002/011891 WO2002091991A2 (en) 2001-05-15 2002-05-15 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use

Publications (1)

Publication Number Publication Date
HK1067492A1 true HK1067492A1 (en) 2005-04-15

Family

ID=26966358

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04108682.2A HK1067492A1 (en) 2001-05-15 2004-11-04 Method of making a homogenous doxorubicin-transferrin conjugate

Country Status (10)

Country Link
US (2) US20040167061A1 (xx)
EP (1) EP1414299B1 (xx)
JP (1) JP2005514322A (xx)
CN (1) CN1307200C (xx)
AT (1) ATE507844T1 (xx)
CA (1) CA2447391C (xx)
DE (1) DE60239938D1 (xx)
HK (1) HK1067492A1 (xx)
PL (1) PL373511A1 (xx)
WO (1) WO2002091991A2 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532245A (ja) 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
CA2447335C (en) 2001-05-15 2011-01-04 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
WO2002091992A2 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
EP1444264A4 (en) * 2001-10-17 2005-10-26 Pharmaceuticals Inc Faulk METHOD AND MATERIALS FOR TARGETING AND INFLUENCING SELECTED CELLS
US9333189B2 (en) * 2010-02-03 2016-05-10 Oncbiomune, Inc. Taxane- and taxoid-protein compositions
JP5378469B2 (ja) * 2011-08-11 2013-12-25 学校法人 日本歯科大学 医療用薬剤
KR20140048404A (ko) * 2012-10-11 2014-04-24 포항공과대학교 산학협력단 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28686A (en) * 1860-06-12 Improvement in steam-radiators
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
JPH0720886B2 (ja) * 1983-08-10 1995-03-08 ペ−ジ フオ−ク，ウオ−ド タンパク質と抗腫瘍剤との複合体
GB8519457D0 (en) * 1985-08-02 1985-09-11 Faulk Ward Page Tumour imaging agents
US5264373A (en) * 1987-02-17 1993-11-23 Abbott Laboratories Fluorescence polarization immunoassay for tetrahydrocannabinoids
US5208323A (en) * 1989-08-10 1993-05-04 Universite Laval Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
US5393737A (en) * 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
AU7475694A (en) * 1993-08-02 1995-02-28 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates
DE69528523T2 (de) * 1994-04-08 2003-06-12 Receptagen Corp Rezeptor modulierendes mitteln und entsprechendes verfahren
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6020316A (en) * 1997-09-25 2000-02-01 Lanks; Karl W. Glutaraldehyde modified chemotherapeutic agents and methods of use thereof
JP2002095476A (ja) * 2000-09-20 2002-04-02 Eisai Co Ltd トランスフェリン受容体を介した遺伝子導入法
JP2004528309A (ja) * 2001-03-23 2004-09-16 ナプロ バイオセラピューティクス，インコーポレイテッド 癌治療用分子複合体
JP2004532245A (ja) * 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
WO2002091992A2 (en) * 2001-05-16 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
EP1444264A4 (en) * 2001-10-17 2005-10-26 Pharmaceuticals Inc Faulk METHOD AND MATERIALS FOR TARGETING AND INFLUENCING SELECTED CELLS

Also Published As

Publication number Publication date
EP1414299A4 (en) 2005-06-22
CN1307200C (zh) 2007-03-28
ATE507844T1 (de) 2011-05-15
US20040167061A1 (en) 2004-08-26
CA2447391C (en) 2012-08-28
WO2002091991A2 (en) 2002-11-21
EP1414299B1 (en) 2011-05-04
PL373511A1 (en) 2005-09-05
CA2447391A1 (en) 2002-11-21
WO2002091991A3 (en) 2004-02-19
EP1414299A2 (en) 2004-05-06
JP2005514322A (ja) 2005-05-19
CN1529551A (zh) 2004-09-15
US20090068104A1 (en) 2009-03-12
DE60239938D1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
WO2003106659A3 (en) TOXIN-APTAMER MOLECULES AND METHODS OF USE THEREOF
ATE473759T1 (de) Bifunktionelle moleküle sowie darauf basierende therapien.
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
MY137552A (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2005116255A3 (en) Aptamer-toxin molecules and method for using same
NO975547D0 (no) Vaksiner med modifiserte meningokokk/polysakkarid-konjugater
ATE478094T1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate,die diese enthalten
NZ288883A (en) Conjugates comprising coagulation factors
DE69904831D1 (de) Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
EP2266624A3 (en) Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
DE69730217D1 (de) Dha-pharmazeutisches produkt konjugate
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
DE60042369D1 (de) Chemisch programmierbare immunität
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
EP1605847A4 (en) PHOTODYNAMIC THERAPY PROVIDED AGAINST ANTIBODIES
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
HK1067492A1 (en) Method of making a homogenous doxorubicin-transferrin conjugate
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
ATE275979T1 (de) Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten
AU2002360350A1 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer
WO1998051792A8 (en) Fac molecules and uses thereof
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους
TWI266801B (en) Polyol-IFN-beta conjugates

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160515